December 8, 2025 Category: FDA Newsletter / Oncology Updates
Hello again, community! If there's one thing certain in modern medicine, it's that it advances quickly. Sometimes so fast that it's hard to keep up.
The link we analyze today is the FDA's "nerve center" for cancer: the page for Oncology and Hematologic Malignancies Approval Notifications. Rather than focusing on a single drug, today we bring you a summary of the most important developments that have appeared on this official listing in recent weeks.
Here are the headlines that are changing cancer and blood disease treatment as we close out the year:
1. New Hope for Amyloidosis (November 19)
One of the most notable additions to the listing is the traditional approval of daratumumab and hyaluronidase-fihj (Darzalex Faspro).
-
The novelty? It is now approved for patients newly diagnosed with light chain amyloidosis (AL), a rare disease where abnormal proteins accumulate in organs.
-
The regimen: It is used in combination with bortezomib, cyclophosphamide, and dexamethasone. It is a major step forward in improving quality of life from initial diagnosis.
2. Advances Against Follicular Lymphoma (November 18)
Lymphoma treatment continues to evolve. The FDA approved the use of epcoritamab-bysp (Epkinly) in combination with lenalidomide and rituximab.
-
For whom? Adults with relapsed or refractory follicular lymphoma (FL).
-
The data: Additionally, traditional approval was granted for its use as monotherapy (single drug) in patients who have already undergone two or more previous lines of treatment.
3. Innovation in Acute Myeloid Leukemia (November 13)
Mid-month, we saw the arrival of ziftomenib (Komzifti), an option directed specifically at cancer genetics.
-
The target: Treat Acute Myeloid Leukemia (AML) in adults with a specific mutation (NPM1) that has relapsed or does not respond to other treatments.
Why Follow This List?
This FDA page is not just an archive; it is the roadmap of new therapies. It allows us to see trends, such as the rise of immunotherapies and "custom-made" treatments based on specific genetic mutations.
Staying informed about these notifications means having access to the newest tools to fight complex diseases, often months or years before they become the common standard worldwide.
Information from: FDA
What's Next?
If you want to train your group of KOLs in impact communication and storytelling, we can schedule an exploratory call to learn about your needs and make you a training proposal. Leaderlix trains leaders from the most emblematic companies in their industries in high-impact presentations.
{% module_block module "widget_de51c720-7f21-48a0-8677-cf70522a806b" %}{% module_attribute "child_css" is_json="true" %}{% raw %}null{% endraw %}{% end_module_attribute %}{% module_attribute "css" is_json="true" %}{% raw %}null{% endraw %}{% end_module_attribute %}{% module_attribute "label" is_json="true" %}{% raw %}null{% endraw %}{% end_module_attribute %}{% module_attribute "meeting" is_json="true" %}{% raw %}"https://leaderlix.com/meetings/gerardo-betancourt/tu-llamada-exploratoria-fda"{% endraw %}{% end_module_attribute %}{% module_attribute "module_id" is_json="true" %}{% raw %}33947244299{% endraw %}{% end_module_attribute %}{% module_attribute "schema_version" is_json="true" %}{% raw %}2{% endraw %}{% end_module_attribute %}{% module_attribute "tag" is_json="true" %}{% raw %}"module"{% endraw %}{% end_module_attribute %}{% end_module_block %}